bhv-7000
Small moleculeexperimental
Clinical trial activity
10 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
4
Phase 4
0
Earliest trial started Dec 31, 2023 (NCT06132893)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07262268 | Phase 1 | Dec 31, 2025 | Biohaven Pharmaceuticals Inc. |
| NCT07125261 | Phase 1 | Oct 7, 2025 | Biohaven Pharmaceuticals Inc., Yale University |
| NCT06423781 | Phase 2 | Aug 1, 2024 | Biohaven Pharmaceuticals Inc. |
| NCT06443463 | Phase 2 | Jul 30, 2024 | Biohaven Pharmaceuticals Inc. |
| NCT06423794 | Phase 2 | Jun 24, 2024 | Biohaven Pharmaceuticals Inc. |
| NCT06425159 | Phase 2/Phase 3 (Phase 3) | Jun 20, 2024 | Biohaven Pharmaceuticals Inc. |
| NCT06419608 | Phase 2 | May 28, 2024 | Biohaven Pharmaceuticals Inc. |
| NCT06419582 | Phase 2/Phase 3 (Phase 3) | May 28, 2024 | Biohaven Pharmaceuticals Inc. |
| NCT06309966 | Phase 2/Phase 3 (Phase 3) | May 13, 2024 | Biohaven Pharmaceuticals Inc. |
| NCT06132893 | Phase 2/Phase 3 (Phase 3) | Dec 31, 2023 | Biohaven Pharmaceuticals Inc. |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biohaven Pharmaceuticals Inc. | For profit | 10 | 9 | 3 | 2023 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1